0
variable(s) selected download| Category | Variable name | variable label (+ explanatory notes) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient data | gebdat | Date of birth | ||||||||||||||||||||||||||||||||
| Patient data | gesl | Sex |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Patient data | iacr | Counts following IACR rules for reporting incidence |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Patient data | incdat | Incidence date
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||||
| Patient data | incjr | Year of incidence
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||||
| Patient data | ink_ses | Median income in postal code area as a proxy for socioeconomic status (SES)
+
Available from 2010. Socioeconomic status (SES) reflects an individual's social position, which strongly influences health and is linked to life expectancy in good health. Research on SES and health typically uses indicators such as education, income, occupation, and material wealth. This variable uses income as a proxy for SES.
Income data by postal code area were obtained from Statistics Netherlands (CBS), with 2019 as the reference year, downloaded on 16 October 2023 via https://www.cbs.nl/nl-nl/dossier/nederland-regionaal/geografische-data
/gegevens-per-postcode.
Income is defined as the median disposable household income, adjusted for household size and composition. For each area, the median standardised household income was compared to the national distribution and classified into one of five groups: low, lower-middle, middle, upper-middle, or high. Income thresholds (in euros) are available at: https://www.cbs.nl/nl-nl/longread/diversen/2023/statistische-gegevens-per-vierkant-en-postcode-2022-2021-2020-2019/4-beschrijving-cijfers. Because postal code areas often have few households, CBS also
considered the 99% confidence interval of the median income. If this interval spans multiple groups, a new category was created to reflect the range (e.g., 'low to lower-middle'). Categories may partially overlap due to this approach. If the median income is based on fewer than 10 households, it is classified as 'unclassifiable'. CBS originally defined 12 income categories.
For this variable, these were reduced to three to simplify analysis and remove overlaps.
Key considerations:
- Income is a snapshot and does not reflect accumulated wealth.
- Data are aggregated by postal code area, which may include substantial variation.
- Household income is strongly age-dependent; analyses should compare individuals within the same age group.
- Median disposable income is considered valid for up to 10 years before and after the reference year (2019).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Patient data | leeft | Age at incidence date | ||||||||||||||||||||||||||||||||
| Patient data | mal | Previous or subsequent malignancies
+
Selection of malignancies to specify in the request:
-Period: Previous and/or subsequent malignancies, or based on a defined timeframe before or around the incidence date.
-Type: All cancer types in the NCR, or all malignant/invasive (excluding skin BCC), or a selection of specific tumour types.
NKR database content with full availability:
Period: Nationwide complete from 1989.
Exclusion criteria:
- Patients residing abroad at the time of incidence
- Basal cell carcinomas of skin and lip
- Second primary invasive and second non-invasive squamous cell carcinomas of the skin
- Adenocarcinoma in situ/high-grade dysplasia of colon, rectosigmoid and rectum
- Carcinoma in situ of the cervix
- Benign/borderline tumours, except: CNS tumours from 2001, Borderline ovarian tumours, AL amyloidosis from 2017, Polymorphic PTLD
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Patient data | mal_incdat | Incidence date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||||
| Patient data | mal_int | Interval between incidence date and date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||||
| Patient data | mal_tumsoort | Tumour type of previous or subsequent malignancy
+
Refers to the NCR tumour classification based on site, morphology, and behaviour. For more information, see: https://iknl.nl/nkr/registratie/tumorindeling
|
||||||||||||||||||||||||||||||||
| Patient data | ovldat | Date of death | ||||||||||||||||||||||||||||||||
| Patient data | post_cijf | Numeric part of the patient's postal code at the time of incidence | ||||||||||||||||||||||||||||||||
| Patient data | vit_stat_dat | Date of vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||||
| Patient data | vit_stat_int | Interval between incidence date and date of vital status (days)
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||||
| Patient data | vit_stat | Vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | topo | Topography excluding sublocation
+
Location of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | topo_sublok | Topography including sublocation
+
Location and sublocation of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | morf | Morphology
+
Histological type of the tumour (first four digits of the ICD-O morphology code) according to ICD-O-3.2.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Tumour data | gedrag | Behaviour
+
Tumour behaviour (fifth digit of the ICD-O morphology code).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ct | cT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | cn | cN (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | cm | cM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pt | pT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pn | pN (TNM)
+
The TNM classification uses the edition applicable at the time of incidence.
Meaning of the last character in pN:
S: Result based only on sentinel node examination (sn)
I: Isolated tumour cells (ITC)
M: Micrometastases (mi)
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pm | pM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | cstadium | Clinical TNM stage
+
cstadium: The clinical stage is based on cTNM, which is derived from information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0. Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM. Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pstadium | Pathological TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
pstadium: The pathological (post-surgical) stage is based on pT, pN and pM. Also in case of pre-surgical therapy, pT and pN are used (ypT and ypN). When no tumour is detectable after pre-surgical therapy, this is shown as pstadium=0.
pM: Indicates whether there is pathological confirmation of distant metastases. There may be distant metastases that are not pathologically confirmed, which are therefore not included in the calculation for this variable.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | stadium | TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
Stadium: Based on pTNM supplemented by cTNM to best reflect the actual stage at diagnosis. Priority is given to pTNM values. If surgery did not occur, pTNM is unknown, or pre-surgical therapy was given (pTNM becomes ypTNM), cTNM values are used.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ond_lymf | Number of regional lymph nodes examined
+
All lymph nodes examined as part of initial diagnostics and treatment combined.
|
||||||||||||||||||||||||||||||||
| Tumour data | pos_biopt_loc | Location of positive prostate biopsy cores
+
Available from incidence year 2020. From incidence date 01-07-2022 onwards, available only for a random sample of all patients with de novo prostate cancer (additionally available on a project basis). This variable includes both ultrasound-guided (systematic/random) biopsies and targeted biopsies. MRI-guided biopsies (MRI in-bore, MRI–TRUS fusion and cognitive fusion) and PSMA PET/CT-guided biopsies are considered targeted biopsies.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pos_lymf | Number of positive regional lymph nodes | ||||||||||||||||||||||||||||||||
| Tumour data | diag_basis | Basis for diagnosis
+
Non-microscopic confirmation:
0 = death certificate only
1 = clinical examination only (medical history and physical)
2 = clinical diagnostic tests, exploratory surgery or autopsy (without microscopic confirmation)
4 = specific biochemical and/or immunological laboratory tests.
Microscopic confirmation:
5 = haematological (bone marrow cytology, e.g., bone marrow aspiration, blood smear) or cytological confirmation of primary tumour or metastases, or definite microscopic confirmation but unclear whether cytology or histology
6 = histological confirmation of metastases only, including at autopsy
7 = histological confirmation of primary tumour, or unclear whether histology refers to primary tumour or
metastasis, including autopsy with histology.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | chaarted | Classification of metastatic disease according to the CHAARTED criteria
+
Since October 2015, the NCR has recorded whether four or more bone metastases are present and whether at least one metastasis is located outside the pelvis and the vertebral column. In addition, the cM stage and the location of metastases are recorded. This enables the classification of metastatic disease according to the CHAARTED criteria.
Note: no distinction is made with regard to the imaging modality (e.g. conventional imaging, PSMA PET/CT) on which the diagnosis of metastases is based.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ct_it | Highest T stage based on either clinical assessment (cT) or imaging (iT)
+
Since incidence year 2019, the T stage based on imaging (iT) has been recorded separately. This change was introduced following a revision of the TNM classification, which stipulates that imaging findings must not be incorporated into the determination of the clinical T stage (cT). In this variable, the highest value of the clinical T stage and the imaging-based T stage has been selected.
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
|
||||||||||||||||||||||||||||||||
| Tumour data | diag_gs_dat | Date of total Gleason score at diagnosis | ||||||||||||||||||||||||||||||||
| Tumour data | diag_psa_dat | Date of PSA measurement at the time of diagnosis | ||||||||||||||||||||||||||||||||
| Tumour data | diag_isup_dat | Date of ISUP grading at diagnosis | ||||||||||||||||||||||||||||||||
| Tumour data | diag_gs | Total Gleason score at diagnosis
+
Available from incidence year 2013. In cases of delayed prostatectomy, the Gleason score is based on data prior to the prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | diag_cr_idc | Invasive cribriform (CR) and/or intraductal carcinoma (IDC) growth at diagnosis
+
Available from incidence date 01-07-2019.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | diag_gs_int | Interval incidence date and total Gleason score assessment at diagnosis (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | diag_isup_int | Interval incidence date and ISUP grading at diagnosis (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | diag_psa_int | Interval incidence date and PSA measurement at diagnosis (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | diag_isup | ISUP grade at diagnosis
+
Available from incidence date 01-10-2015. In cases of delayed prostatectomy, the Gleason score is based on data prior to prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | diag_gs_prim | Primary Gleason pattern at diagnosis
+
Available from incidence date 01-10-2015. In cases of delayed prostatectomy, the Gleason score is based on data prior to prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | diag_psa | PSA level at diagnosis (µg/L)
+
Available from incidence year 2005. In the case of delayed prostatectomies, this concerns the PSA value based on data prior to the prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onward.
0 = undetectable (valid from 01-10-2015)
999 = >999 (valid until 01-10-2015)
9998 = >10.000 (valid from 16-04-2016)
|
||||||||||||||||||||||||||||||||
| Tumour data | diag_ct_it_risicogroep | Risk group based on the highest of cT and iT at diagnosis
+
Available from incidence year 2013. In the case of delayed prostatectomies, this concerns the risk group based on data prior to the prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onward.
Since incidence year 2019, the T stage based on imaging (iT) has been recorded separately. The reason for this is a change in the TNM classification, which stipulates that imaging may not be included when determining the clinical T stage (cT). In this variable, the highest value of the clinical T stage and the imaging-based T stage has been used to classify tumors in accordance with the EAU risk classification.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | diag_eau_risicogroep | EAU risk group at diagnosis
+
Available from incidence year 2013. In the case of delayed prostatectomies, this concerns the risk group based on data prior to the prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onward.
Note: from incidence year 2019 onward, imaging may no longer be included in determining the clinical T stage (cT). This results in a shift in risk group classification from 2018 to 2019. For a more uniform classification, the risk group at diagnosis based on the highest of cT and iT can be used.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | diag_gs_sec | Secondary Gleason pattern at diagnosis
+
Available from incidence date 01-10-2015. In cases of delayed prostatectomy, the Gleason score is based on data prior to prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | echo_biopt_pos | Number of positive ultrasound-guided prostate biopsy cores
+
Available from incidence year 2013 through 2019. If biopsies were performed multiple times, the session with the highest number of positive biopsies / the most extensive localization of positive biopsies was selected, followed by the session with the earliest date or the date closest to diagnosis.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | it | T stage based on imaging (iT)
+
Since incidence year 2019, the T stage (iT) has been recorded separately on the basis of imaging. The reason for this is a change in the TNM classification, which stipulates that imaging should not be taken into account when determining the clinical T stage (cT).
For TNM classification, the edition applicable at the time of incidence was used. From 2017 onwards, this has been the 8th edition of the TNM classification (TNM 8).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_bot | Bone metastasis/metastases present
+
From incidence year 2015 onwards, the topography of distant metastases has been recorded as a standard item. Prior to 2010, registration was not mandatory, and up to and including 2014 a maximum of three topographical sites were recorded.
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_bot_incdat | Incidence date of bone metastasis/metastases
+
Earliest known date on which a bone metastasis was diagnosed, in the period prior to progression and up to a maximum of 91 days after incidence of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | meta_lymf_incdat | Incidence date of non-regional lymph node metastasis/metastases
+
Earliest known date on which a non-regional lymph node metastasis was diagnosed, in the period prior to progression and up to a maximum of 91 days after incidence of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | meta_visc_incdat | Incidence date of visceral metastasis/metastases
+
Earliest known date on which a visceral metastasis was diagnosed, in the period prior to progression and up to a maximum of 91 days after incidence of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | meta_visc_int | Interval incidence date of the primary tumour and detection of visceral metastasis/metastases (days)
+
Interval based on the earliest known date on which a visceral metastasis was diagnosed, in the period prior to progression and up to a maximum of 91 days after incidence of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | meta_lymf_int | Interval incidence date of the primary tumour and non-regional lymph node metastasis/metastases (days)
+
Interval based on the earliest known date on which a non-regional lymph node metastasis was diagnosed, in the period prior to progression and up to a maximum of 91 days after incidence of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | meta_bot_int | Interval incidence date of the primary tumour and bone metastasis/metastases (days)
+
Interval based on the earliest known date on which a bone metastasis was diagnosed, in the period prior to progression and up to a maximum of 91 days after incidence of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Tumour data | meta_lymf | Non-regional lymph node metastasis/metastases present
+
From incidence year 2015 onwards, the topography of distant metastases has been recorded as a standard item. Prior to 2010, registration was not mandatory, and up to and including 2014 a maximum of three topographical sites were recorded.
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_visc | Visceral metastasis/metastases present
+
Visceral metastases are defined as distant metastases other than bone metastases and non-regional lymph node metastases.
From incidence year 2015 onwards, the topography of distant metastases has been recorded as a standard item. Prior to 2010, registration was not mandatory, and up to and including 2014 a maximum of three topographical sites were recorded.
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_tum_afm | Tumour size based on MRI imaging (mm)
+
Available from incidence date 01-07-2019 up to 30-06-2022; thereafter available only on a project basis. This variable describes the largest dimension of the largest lesion.
|
||||||||||||||||||||||||||||||||
| Tumour data | mri_epe | Suspicion of extraprostatic extension based on MRI imaging
+
Available from incidence date 01-07-2019. Invasion of the seminal vesicles (SVI) is not taken into consideration here.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_pirads_links | Left-sided PI-RADS score based on MRI imaging
+
Available from incidence date 01-07-2019 up to 30-06-2022. This variable describes the highest left-sided PI-RADS score, primarily based on the conclusion of the radiology report.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_m | M stage based on MRI imaging (TNM)
+
Available from incidence date 01-07-2019 up to 30-06-2022; thereafter available only on a project basis. The stage is recorded as literally stated or described in the report. The TNM classification edition applicable at the time of incidence was used. From 2017 onwards this is the 8th edition (TNM 8).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_n | N stage based on MRI imaging (TNM)
+
Available from incidence date 01-07-2019 up to 30-06-2022; thereafter available only on a project basis. The stage is recorded as literally stated or described in the report. The TNM classification edition applicable at the time of incidence was used. From 2017 onwards this is the 8th edition (TNM 8).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_pirads | Overall PI-RADS score based on MRI imaging
+
Available from incidence date 01-07-2019. This variable describes the overall highest PI-RADS score, primarily based on the conclusion of the radiology report.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_psad | PSA density based on MRI imaging (ng/ml2)
+
Available from incidence date 01-07-2019 up to 30-06-2022. This variable describes the PSA density if reported in the MRI report.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_pirads_rechts | Right-sided PI-RADS score based on MRI imaging
+
Available from incidence date 01-07-2019 up to 30-06-2022. This variable describes the highest right-sided PI-RADS score, primarily based on the conclusion of the radiology report.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_t | T stage based on MRI imaging (TNM)
+
Available from incidence date 01-07-2019 up to 30-06-2022; thereafter available only on a project basis. The stage is recorded as literally stated or described in the report. The TNM classification edition applicable at the time of incidence was used. From 2017 onwards this is the 8th edition (TNM 8).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mri_tum_vol | Tumour volume based on MRI imaging (mL)
+
Available from incidence date 01-07-2019 up to 30-06-2022.
|
||||||||||||||||||||||||||||||||
| Tumour data | mri_prost_vol | Prostate volume based on MRI imaging (mL)
+
Available from incidence date 01-07-2019.
|
||||||||||||||||||||||||||||||||
| Tumour data | mri_dominante_zijde | Dominant side based on MRI imaging
+
Available from incidence date 01-07-2019 up to 30-06-2022. This variable describes which side shows the most unfavourable characteristics (highest T stage / highest PI-RADS score).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pros_gs_delta | Difference between Gleason score at prostatectomy and Gleason score at diagnosis
+
Available from incidence year 2013. In cases of delayed prostatectomy, the Gleason score used is based on data prior to the prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | biopt | Prostate biopsies taken
+
Available from incidence year 2013. From the incidence date of 1 July 2022 onwards, this variable is only available for a random sample of all patients with de novo prostate cancer (and in addition also available on a project-specific basis). This variable describes whether prostate biopsies were taken before or on the start date of the first tumour directed therapy with a known date, and within 3 months of diagnosis.
Tumour directed therapy is defined as therapy that is intended to be curative or aims to slow disease progression and/or prolong life. This includes: surgery of the primary tumour, radiotherapy to the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapy.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | contact_zkh1 | Hospital of first contact regarding malignancy
+
The first hospital visited by the patient for symptoms related to the malignancy, and where, based on that visit, a (suspected) malignancy is determined.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | echo_biopt_afgenomen | Number of ultrasound-guided prostate biopsy cores taken
+
Available from incidence year 2013 through 2019. If biopsies were performed on multiple occasions, the session with the highest number of positive biopsies and/or the most extensive localisation of positive biopsies was selected, followed by the session with the earliest date or the date closest to diagnosis.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | echo_biopt | Ultrasound-guided prostate biopsies taken
+
Available from incidence year 2013. From incidence date 01 07 2022 onward, this variable is only available for a random sample of all patients with de novo prostate cancer (and in addition also available on a project-specific basis). This variable describes whether ultrasound guided prostate biopsies were performed before or on the start date of the first tumour directed therapy, with a known date, and within 3 months after diagnosis.
In the period from 2013 through September 2015, no distinction was made between ultrasound guided biopsies (also referred to as random or systematic biopsies) and targeted biopsies. For this period, we assume that these concern ultrasound guided biopsies.
Tumour directed therapy is defined as therapy that is intended to be curative or aims to slow disease progression and/or prolong life. This includes: surgery of the primary tumour, radiotherapy to the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | echo_biopt_dat | Date of ultrasound-guided prostate biopsy sampling
+
Available from incidence year 2013. From incidence date 01-07-2022 onwards, available only for a random sample of all patients with de novo prostate cancer (additionally available on a project basis). If biopsies were performed on multiple occasions, the session with the highest number of positive cores and/or the most extensive localisation of positive biopsy cores was selected, followed by the session with the earliest date or the date closest to diagnosis.
|
||||||||||||||||||||||||||||||||
| Process data | echo_biopt_int | Interval incidence date and date of ultrasound-guided prostate biopsy sampling (days)
+
Available from incidence year 2013. From incidence date 01-07-2022 onwards, available only for a random sample of all patients with de novo prostate cancer (additionally available on a project basis). If biopsies were performed on multiple occasions, the session with the highest number of positive cores and/or the most extensive localisation of positive biopsy cores was selected, followed by the session with the earliest date or the date closest to diagnosis. The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Process data | gericht_biopt | Targeted prostate biopsies taken
+
Available from incidence date 01-10-2015. From incidence date 01-07-2022 onward, this variable is only available for a random sample of all patients with de novo prostate cancer (and in addition also available on a project-specific basis). This variable describes whether targeted prostate biopsies with a known date were taken before or on the start date of first tumour-directed therapy and within 3 months after diagnosis. MRI-guided (MRI in-bore, MRI-TRUS fusion, and cognitive fusion biopsies) and PSMA PET/CT-guided biopsies are considered targeted biopsies.
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | gericht_biopt_dat | Date of targeted prostate biopsy sampling
+
Available from incidence date 01-10-2015. From incidence date 01-07-2022 onwards, available only for a random sample of all patients with de novo prostate cancer (additionally available on a project basis). If biopsies were performed on multiple occasions, the session with the most extensive localisation of positive biopsy cores (from incidence year 2020 onwards) was selected, followed by the session with the earliest date or the date closest to diagnosis.
|
||||||||||||||||||||||||||||||||
| Process data | gericht_biopt_int | Interval incidence date and date of targeted prostate biopsy sampling (days)
+
Available from incidence date 01-10-2015. From incidence date 01-07-2022 onwards, available only for a random sample of all patients with de novo prostate cancer (additionally available on a project basis). If biopsies were performed on multiple occasions, the session with the most extensive localisation of positive biopsy cores (from incidence year 2020 onwards) was selected, followed by the session with the earliest date or the date closest to diagnosis. The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Process data | mdo | Discussed in multidisciplinary team meeting
+
Available from incidence date 01-10-2015 up to 30-06-2022; thereafter available only on a project basis. As a rule, the most recent MDT meeting in which a treatment decision was made is recorded. If no MDT meeting took place before the start of therapy, the first MDT meeting held after the start of therapy is recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | mdo_dat | Date of multidisciplinary team meeting
+
Available from incidence date 01-10-2015 up to 30-06-2022; thereafter available only on a project basis. As a rule, the most recent MDT meeting in which a treatment decision was made is recorded. If no MDT meeting took place before the start of therapy, the first MDT meeting held after the start of therapy is recorded.
|
||||||||||||||||||||||||||||||||
| Process data | mdo_int | Interval incidence date and date of the multidisciplinary team (MDT) meeting (days)
+
Available from incidence date 01-10-2015 up to 30-06-2022; thereafter available only on a project basis. As a rule, the most recent MDT meeting in which a treatment decision was made is recorded. If no MDT meeting took place before the start of therapy, the first MDT meeting held after the start of therapy is recorded. The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Process data | mdo_zkh | Hospital where the multidisciplinary team meeting took place
+
Available from incidence date 01-10-2015 up to 30-06-2022; thereafter available only on a project basis. As a rule, the most recent MDT meeting in which a treatment decision was made is recorded. If no MDT meeting took place before the start of therapy, the first MDT meeting held after the start of therapy is recorded. If a patient was discussed in a regional MDT meeting, the hospital from which the patient was referred is recorded, regardless of where the MDT meeting took place.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | mri | MRI scan performed
+
Available from incidence date 01-07-2019. Since the incidence date of 01 07 2019, all MRI scans performed for the purpose of diagnosis and/or evaluation of prostate cancer have been recorded, covering the period from one year prior to diagnosis up to the registration moment (approximately 7 to 9 months after diagnosis). This variable describes whether: (1) a prostate MRI was performed on or before the incidence date, or (2) an MRI scan was performed on or before the start date of the first tumour directed therapy with a known date and within 3 months after diagnosis. MRI scans performed for the purpose of direct MRI guided biopsies and radiotherapy planning are not recorded.
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | mri_dat | Date of MRI scan
+
Available from incidence date 01-07-2019. If multiple scans were performed before or on the incidence date, the most recently performed MRI scan was selected. If no scan was performed before or on the incidence date, but multiple scans were performed before or on the start date of first tumour-directed therapy with a known date ánd within 3 months after diagnosis, the earliest performed MRI scan was selected.
|
||||||||||||||||||||||||||||||||
| Process data | mri_diag | Diagnostic MRI scan performed
+
Available from incidence date 01-07-2019. This variable describes whether an MRI scan was performed before or on the incidence date.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | mri_int | Interval incidence date and date of MRI scan (days)
+
Available from incidence date 01-07-2019. If multiple scans were performed before or on the incidence date, the most recently performed MRI scan was selected. If no scan was performed before or on the incidence date, but multiple scans were performed before or on the start date of first tumour-directed therapy with a known date ánd within 3 months after diagnosis, the earliest performed MRI scan was selected.
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Process data | mri_zkh | Hospital where the MRI scan was performed
+
Available from incidence date 01-07-2019
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | psma | PSMA PET/CT scan performed
+
Since 01-01-2022, it has been recorded whether a PSMA PET/CT scan was performed (from 01-07-2019 this was recorded only in the context of clinical studies). However, this information is not available for all patients. This variable describes whether a PSMA PET/CT scan was performed within 6 months after diagnosis.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | psma_meta_bot | Bone metastases based on PSMA PET/CT imaging
+
Available from incidence date 01-01-2022 (from 01-07-2019 onwards only on a project basis). This variable describes the presence of bone abnormalities consistent with prostate cancer.
|
||||||||||||||||||||||||||||||||
| Process data | psma_dat | Date of PSMA PET/CT scan
+
Available from incidence date 01-01-2022 (from 01-07-2019 onwards only on a project basis). This variable describes the PSMA PET/CT scan performed within 6 months after diagnosis. If multiple scans were performed within 6 months after diagnosis, the PSMA PET/CT scan most recently performed before the start of tumour-directed therapy was recorded.
|
||||||||||||||||||||||||||||||||
| Process data | psma_int | Interval incidence date and PSMA PET/CT scan (days)
+
Available from incidence date 01-01-2022 (from 01-07-2019 onwards only on a project basis). This variable describes the PSMA PET/CT scan performed within 6 months after diagnosis. If multiple scans were performed within 6 months after diagnosis, the PSMA PET/CT scan most recently performed before the start of tumour-directed therapy was selected.
|
||||||||||||||||||||||||||||||||
| Process data | psma_nrln | Non-regional lymph node metastases based on PSMA PET/CT imaging
+
Available from incidence date 01-01-2022 (from 01-07-2019 onwards only on a project basis). This variable describes the presence of non-regional lymph node abnormalities consistent with prostate cancer.
|
||||||||||||||||||||||||||||||||
| Process data | psma_prost | Prostatic abnormality based on PSMA PET/CT imaging
+
Available from incidence date 01-01-2022 (from 01-07-2019 onwards only on a project basis). This variable describes the presence of prostate abnormalities consistent with prostate cancer.
|
||||||||||||||||||||||||||||||||
| Process data | psma_rln | Regional lymph node metastases based on PSMA PET/CT imaging
+
Available from incidence date 01-01-2022 (from 01-07-2019 onwards only on a project basis). This variable describes the presence of non-regional lymph node abnormalities consistent with prostate cancer.
|
||||||||||||||||||||||||||||||||
| Process data | psma_meta_visc | Visceral metastases based on PSMA PET/CT imaging
+
Available from incidence date 01-01-2022 (from 01-07-2019 onwards only on a project basis). This variable describes the presence of other soft tissue abnormalities consistent with prostate cancer.
|
||||||||||||||||||||||||||||||||
| Process data | psma_zkh | Hospital where the PSMA PET/CT scan was performed
+
Available from incidence date 01-01-2022 (from 01-07-2019 onwards only on a project basis).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | zkh_patnum | Patient number in hospital | ||||||||||||||||||||||||||||||||
| Treatment data | as_ww | Active surveillance or watchful waiting strategy performed
+
In addition to active surveillance and watchful waiting, best supportive care is also included in this variable. This comprises only palliative interventions/therapies (primarily aimed at symptom management). The treatment strategies defined here may be combined with a diagnostic procedure (e.g. lymph node dissection).
In principle, the NCR records the primary treatment. However, if tumour-directed therapy is initiated before the time of registration (approximately 7 to 9 months after diagnosis) and this is not due to disease progression, the tumour-directed therapy is also recorded. Patients who were initially managed with active surveillance, watchful waiting, or best supportive care and who switch to tumour-directed therapy within 6 months after diagnosis are classified as no (0). In this situation, the therapy to which they switch is considered part of the primary treatment plan. This is in line with the PRIAS follow-up protocol (version 6.0), which recommends assessing PSA levels, performing a digital rectal examination (DRE), and evaluating the treatment strategy 6 months after diagnosis.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chemo | Systemic chemotherapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_toeval | Tumour was an incidental finding during surgery for another indication |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | cyst | Cystoprostatectomy performed
+
A cystoprostatectomy is performed almost exclusively because another urogenital malignancy is (also) present; prostate cancer is frequently an incidental finding.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | horm | Systemic hormonal therapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation)are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | lkd | Pelvic lymph node dissection performed
+
Available from incidence year 1999.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | lkd_omvang | Extent of pelvic lymph node dissection
+
Available from incidence date 01-10-2015. From incidence date 01-07-2022 onwards, available only for a random sample of all patients with de novo prostate cancer (additionally available on a project basis). The extent is recorded as limited if a limited (obturator nodes) or standard (obturator + external iliac nodes) lymph node dissection was performed. The extent is recorded as extended if an extended (obturator + external iliac + internal iliac nodes) or super-extended (obturator + external iliac + internal iliac + common iliac + presacral nodes) lymph node dissection was performed.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | meta_rt | Radiotherapy targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | postchir_psa_dat | Date of post-surgical PSA measurement
+
Available from incidence date 01-10-2015.
|
||||||||||||||||||||||||||||||||
| Treatment data | postchir_psa_int | Interval incidence date and post-surgical PSA measurement (days)
+
Available from incidence date 01-10-2015.
|
||||||||||||||||||||||||||||||||
| Treatment data | postchir_psa | Post-surgical PSA level (µg/L)
+
Available from incidence date 01-10-2015.
The post-surgical value refers to the lowest PSA level measured in the period 3 to 7 months after prostatectomy. Unless: a) undetectably low PSA values (<0.1 µg/l) were already measured within 3 months. In that case, the first undetectably low value is selected. Or b) PSA was not measured in the period 3 to 7 months after prostatectomy. In that case, the lowest PSA value measured within 3 months is selected.
|
||||||||||||||||||||||||||||||||
| Treatment data | postchir_6mnd_psa_verhoogd | PSA elevated 6 months after prostatectomy
+
Available from 1 July 2019 onwards, based on the date of surgery.
The PSA value 6 months (± 1 month) after prostatectomy. Considered elevated if >?0.1 µg/L. If no PSA measurement is available in the period 5 to 7 months after prostatectomy, the value is, where possible, derived from the last measurement before 5 months and the first measurement after 7 months (see value list). PSA values >?0.1 µg/L within 3 months after prostatectomy are excluded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros | Prostatectomy performed
+
Cystoprostatectomies are excluded. Up to incidence year 2013, only prostatectomies that were part of the initial treatment plan were recorded. From incidence year 2013 onwards, all prostatectomies performed are recorded. So-called delayed prostatectomies are not included in the standard data delivery but can be provided upon request.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_tum_afm | Tumour size based on prostatectomy specimen (mm)
+
Available from incidence date 16-04-2016 up to 31-12-2019.
|
||||||||||||||||||||||||||||||||
| Treatment data | pros_bloed | Perioperative blood loss during prostatectomy (mL)
+
Available from incidence date 01-10-2015 up to 31-12-2022.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_cad_dat | Date of catheter (CAD) removal after prostatectomy
+
Available from incidence date 01-10-2015 up to 31-12-2022.
01-01-1900 = date unknown / not applicable
|
||||||||||||||||||||||||||||||||
| Treatment data | pros_dat | Date of prostatectomy | ||||||||||||||||||||||||||||||||
| Treatment data | pros_isup_delta | Difference between ISUP grade at prostatectomy and ISUP grade at diagnosis
+
Available from incidence date 01-10-2015. In cases of delayed prostatectomy, the ISUP grade is based on data prior to prostatectomy. This information is available for delayed prostatectomies performed from 01-01-2023 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_duur | Duration of prostatectomy (minutes)
+
Available from incidence date 01-10-2015 up to and including 31-12-2022; thereafter available only on a project basis.
|
||||||||||||||||||||||||||||||||
| Treatment data | pros_gs | Total Gleason score at prostatectomy
+
Available from incidence year 2013.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_cr_idc | Invasive cribriform (CR) and/or intraductal carcinoma (IDC) growth at prostatectomy
+
Available from 01-01-2013 onwards, based on the date of surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_int | Interval incidence date and date of prostatectomy (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | pros_cad_int | Interval incidence date and date of catheter removal after prostatectomy (days)
+
Available from incidence date 01-10-2015 up to 31-12-2022. The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | pros_isup | ISUP grade at prostatectomy
+
Available from incidence date 01-10-2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_jr | Year of prostatectomy | ||||||||||||||||||||||||||||||||
| Treatment data | pros_ns | Nerve-sparing (NS) surgery performed at prostatectomy
+
Available from incidence date 01-10-2015
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_opnameduur | Length of hospital stay after prostatectomy (days) | ||||||||||||||||||||||||||||||||
| Treatment data | pros_gs_prim | Primary Gleason pattern at prostatectomy
+
Available from incidence date 01-10-2015
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_rad | Radicality of prostatectomy
+
Available from incidence date 01-10-2015. This item is used for invasive tumours to indicate whether residual tumour is present after a resection aimed at the primary tumour (T). This item does not concern regional lymph nodes or distant metastases. In determining radicality, only the invasive primary tumour is considered. Any in situ component or lymph nodes in the resection specimen are not included in the assessment of the item "radicality of the primary tumour".
Microscopically radical resection: When the pathologist reports that the resection margins are free and/or that the procedure was radical, and the surgeon does not indicate in the operative report that macroscopic residual tumour may have been left behind.
Microscopically irradical resection: When the pathologist reports that the resection margins are not free and/or that the procedure was not radical, and the surgeon does not indicate in the operative report that macroscopic residual tumour may have been left behind.
Macroscopically irradical resection:When the surgeon states in the operative report that macroscopic residual tumour was left behind due to an incomplete resection of the primary tumour, or when the surgeon does not mention this in the operative report but it is described in the macroscopic section of the pathology report.
Up to incidence date 15-04-2016, only information from the pathology report was used to determine radicality.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_heropname_reden | Reason for readmission after prostatectomy
+
Available from incidence date 16-04-2016. Up to operative date 30-06-2019, readmissions within 30 days after prostatectomy were recorded. From operative date 01-07-2019 onwards, readmissions within 90 days after prostatectomy are recorded. The routine admission for catheter removal (CAD) after prostatectomy is not counted as a readmission.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_gs_sec | Secondary Gleason pattern at prostatectomy
+
Available from incidence date 01-10-2015
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_chir_tech | Surgical technique of prostatectomy
+
Available up to incidence date 30-06-2023; thereafter available only on a project basis. The distinction between open and (conventional) laparoscopic surgery can be made from 2010 onwards, and conversion status from 2015. From 2014 onwards, it has been routinely recorded whether surgery was robot-assisted.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_gs_ter | Tertiary Gleason pattern at prostatectomy
+
Available from incidence date 01-10-2015
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | pros_tum_vol | Tumour volume based on prostatectomy specimen (%)
+
Available from incidence date 16-04-2016 up to 31-12-2019.
996 = volume percentage is <25%
997 = volume percentage is 25-50%
998 = volume percentage is 50%
999 = unknown / not reported
|
||||||||||||||||||||||||||||||||
| Treatment data | pros_zkh | Hospital where prostatectomy was performed |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | rt | Radiotherapy classified as pre- or post-surgical
+
This variable refers to radiotherapy targeting the primary tumour.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | rt_start_int[1-n] | Interval between incidence date and start date of radiotherapy (days)[1-n] | ||||||||||||||||||||||||||||||||
| Treatment data | rt_stop_int[1-n] | Interval between incidence date and end date of radiotherapy (days)[1-n] | ||||||||||||||||||||||||||||||||
| Treatment data | rt_startdat[1-n] | Start date of radiotherapy[1-n] | ||||||||||||||||||||||||||||||||
| Treatment data | rt_stopdat[1-n] | End date of radiotherapy[1-n] | ||||||||||||||||||||||||||||||||
| Treatment data | rt_type[1-n] | Type of radiotherapy[1-n] | ||||||||||||||||||||||||||||||||
| Treatment data | rt_zkh[1-n] | Hospital where radiotherapy was performed[1-n] | ||||||||||||||||||||||||||||||||
| Treatment data | syst_code | Code for systemic therapy
+
Systemic therapies in the NCR are coded using the Anatomical Therapeutic Chemical (ATC) classification system. Recording of systemic therapy is not always specific; before 2015, non-specific codes were used more frequently.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Treatment data | syst_start_int | Interval between incidence date and start date of systemic therapy (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | syst_stop_int | Interval between incidence date and end date of systemic therapy (days)
+
The end date of chemotherapy is the day the final cycle is completed. If this date is unknown, the start date of the last cycle may be recorded as the end date. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | syst_startdat | Start date of systemic therapy | ||||||||||||||||||||||||||||||||
| Treatment data | syst_stopdat | End date of systemic therapy
+
The end date of chemotherapy is the day the final cycle is completed. If this date is unknown, the start date of the last cycle may be recorded as the end date.
|
||||||||||||||||||||||||||||||||
| Treatment data | syst_zkh | Hospital where systemic therapy was administered |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | ther_type | Type of therapy
+
The initial treatment of prostate cancer, classified into categories.
For outcome value 0 (active surveillance/watchful waiting/best supportive care), see variable: as_ww.
For outcome value 88 (cystoprostatectomy), see variable: cyst.
For the combination of androgen deprivation therapy (ADT) with an androgen receptor pathway inhibitor (ARPi) and/or chemotherapy, possibly in combination with radiotherapy, a period of 6 months was used between the start date of ADT and the start date of the ARPi/chemotherapy.
Only taxanes and chemotherapy not otherwise specified (incidentally recorded since incidence year 2016) were classified as chemotherapy. If another type of chemotherapy was administered within a period of 6 months after the start of ADT or any other local therapy, the treatment was categorised as other.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther_bekend_int1 | Interval incidence date and first known date of tumour-directed therapy (days)
+
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded. The incidence date is defined as the date of the first histological or
cytological confirmation of the primary tumor.
|
||||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther_start_int1 | Interval incidence date and start date of first tumour-directed therapy (days)
+
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|
||||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther_startdat1 | Start date of first tumour-directed therapy
+
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|
||||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther_bekend_startdat1 | Start date of first tumour-directed therapy with known date
+
Tumour directed therapy is defined as therapy intended to be curative or aimed at delaying progression and/or prolonging survival. This includes: surgery of the primary tumour, radiotherapy of the primary tumour, systemic therapy, unknown therapy, and other local tumour directed therapies.
Diagnostic procedures (e.g. lymph node dissection) or purely palliative interventions/therapies (primarily aimed at symptom control) are not considered tumour directed therapy. Active surveillance and watchful waiting strategies are also excluded.
|